Research on GLP-1 receptor agonists and the gut microbiome reveals several consistent patterns
Hydrogen sulfide can be generated when microorganisms process sulfur-containing compounds, but odor alone cannot identify the exact organism, location, or disease
The blood-vessel signaling associated with GHK-Cu, BPC-157, and TB-4 creates a theoretical concern, not a measured human tumor risk
These findings are further supported by another sub-analysis of SURMOUNT1, which reported a 33.9% (8.2% for placebo) reduction in fat mass and a 10.9% (2.6% for placebo) reduction in lean mass by week 72, with approximately 75% of weight loss attributable to fat mass, consistent across clinically relevant subgroups [68]
Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement multidisciplinary consensus statement